2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-18053
    AZD 4017 1024033-43-9 98.89%
    AZD 4017 is a potent, selective 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) inhibitor, with an IC50 of 7 nM.
    AZD 4017
  • HY-42680
    D-Tagatose 87-81-0 ≥98.0%
    D-Tagatose (D-(-)-Tagatose) is a rare monosaccharide found in nature with prebiotic characteristics. D-Tagatose is as a substitute for sucrose and a low-calorie sweetener in foodstuffs such as gum, fruit juice, and beverages. D-Tagatose is also a potential antidiabetic agent for the research of type II diabetes and a prebiotic to help elevate beneficial bacteria in the colon, prevent colon cancer, and lower cholesterol.
    D-Tagatose
  • HY-44170
    Pantothenate kinase-IN-2 902614-04-4
    Pantothenate kinase-IN-2 is a potent Pantothenate kinase 1/3 (PanK1/3) inhibitor with an IC50 of 0.14 μM and 0.36 μM. Pantothenate kinase-IN-2 is a promising agent for PKAN (PanK-associated neurodegeneration) and diabetes research.
    Pantothenate kinase-IN-2
  • HY-B0025
    Voglibose 83480-29-9 ≥98.0%
    Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis.
    Voglibose
  • HY-B0119
    Risedronic acid sodium 115436-72-1 ≥98.0%
    Risedronic acid (Risedronate) sodium, a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid sodium suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid sodium inhibits blood stages of Plasmodium falciparum (IC50 of 20.3 μM). Risedronic acid sodium inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins.
    Risedronic acid sodium
  • HY-B1671
    (+)-Kavain 500-64-1 ≥99.0%
    (+)-Kavain, a main kavalactone extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na+ and Ca2+ channels. (+)-Kavain is shown to bind at the α4β2δ GABAA receptor and potentiate GABA efficacy. (+)-Kavain is used as a treatment for inflammatory diseases, its anti-inflammatory action has been widely studied.
    (+)-Kavain
  • HY-B1898
    Metadoxine 74536-44-0 99.88%
    Metadoxine blocks adipocyte differentiation in association with inhibition of the protein kinase A-cAMP response element binding protein (PKA-CREB) pathway.
    Metadoxine
  • HY-N0807
    Swertiamarin 17388-39-5 99.03%
    Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating JAK2/STAT3 transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis.
    Swertiamarin
  • HY-N2534
    Karanjin 521-88-0 ≥99.0%
    Karanjin is an orally active furanoflavonoid which can be isolated from several Leguminosae. Karanjin exhibits evident anti-diabetic, anti-cancer, anti-inflammatory, antioxidant, anticolitis, anti-ulcer, anti-Alzheimer properties and multiple insect repellent/insecticidal, acaricide properties, suggesting the potential of Karanjin to be applied to relevant research.
    Karanjin
  • HY-N7108
    7-Hydroxyflavone 6665-86-7 99.84%
    7-Hydroxyflavone is a flavonoid isolated from Clerodendrum phlomidis, with anti-inflammatory activity. 7-Hydroxyflavone protects renal cells from nicotine (NIC)-associated cytotoxicity via the ERK/Nrf2/HO-1 pathway. 7-Hydroxyflavone inhibits PKM2 with an IC50 of 2.12 μM. 7-Hydroxyflavone inhibits COX-2 and 5-LOX with IC50 of 27 µg/mL and 33 µg/mL. 7-Hydroxyflavone is orally active.
    7-Hydroxyflavone
  • HY-101082
    N6,2′-O-Dimethyladenosine 57817-83-1 99.93%
    N6,2′-O-Dimethyladenosine is a substrate of fat mass and obesity-associated gene (FTO) and mRNA cap modification. N6,2′-O-Dimethyladenosine dynamically regulates mRNA stability, translation efficiency, and protein expression. N6,2′-O-Dimethyladenosine can regulate obesity.
    N6,2′-O-Dimethyladenosine
  • HY-101666
    HBX 41108 924296-39-9 98.91%
    HBX 41108 is an inhibitor of ubiquitin-specific protease 7 (USP7) with an IC50 of 424 nM. HBX 41108 inhibits USP7-mediated p53 deubiquitination to stabilize p53 and inhibits cancer cell growth. BX 41108 can be used in cancer and diabetes research.
    HBX 41108
  • HY-109561
    Pegaptanib sodium 222716-86-1 98.09%
    Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .
    Pegaptanib sodium
  • HY-110228
    Metformin-d6 hydrochloride 1185166-01-1 98.79%
    Metformin-d6 hydrochloride is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.
    Metformin-d6 hydrochloride
  • HY-113204
    N-Oleoyl glycine 2601-90-3 ≥99.0%
    N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte.
    N-Oleoyl glycine
  • HY-N10574
    Queuine 72496-59-4 99.67%
    Queuine is a selective substrate for tRNA guanine transglycosylase (TGT) and can be incorporated into eukaryotic tRNA. Queuine promotes tRNA modification, affecting mitochondrial function and Warburg metabolic phenotype. If Queuine is deficient, aerobic glycolysis can be enhanced, oxidative phosphorylation can be inhibited, and Warburg metabolism can be promoted, accompanied by increased ammonia and lactate production and increased lactate dehydrogenase activity. Queuine can be used for autoimmune diseases (such as experimental models of multiple sclerosis) and cancer metabolic regulation, and its deficiency is associated with low tRNA modification in tumor cells.
    Queuine
  • HY-Y0337S
    L-Cysteine-13C3,15N 202406-97-1 99.9%
    L-Cysteine-13C3,15N is the 13C- and 15N-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans.
    L-Cysteine-13C3,15N
  • HY-113165A
    Isobutyryl-L-carnitine chloride 6920-31-6 ≥98.0%
    Isobutyryl-L-carnitine chloride is a product of the acyl-CoA dehydrogenases.
    Isobutyryl-L-carnitine chloride
  • HY-N0390S9
    L-Glutamine-15N-1 59681-32-2 ≥98.0%
    L-Glutamine-15N-1 is the 15N-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells.
    L-Glutamine-15N-1
  • HY-W013100
    Cytidine-5'-triphosphate disodium 36051-68-0 ≥98.0%
    Cytidine-5'-triphosphate (Cytidine triphosphate; 5'-CTP) disodium is a nucleoside triphosphate, that is invovled in biosynthesis of DNA, RNA and lipid. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate disodium is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii.
    Cytidine-5'-triphosphate disodium
Cat. No. Product Name / Synonyms Application Reactivity